Gwendolyn Wu
Senior reporterGwendolyn is a senior reporter at BioPharma Dive covering biotech startups, venture capital and the ecosystem that supports them. Previously, she authored Bay Briefing, the San Francisco Chronicle’s flagship weekday newsletter, and covered COVID-19 and the business of healthcare for the Houston Chronicle. Outside of the newsroom, Gwendolyn teaches at the California Scholastic Press Association summer workshop for high school journalists, and has led student and early career programs for the Asian American Journalists Association. She has degrees in history and sociology from the University of California at Santa Barbara.
358 articles by Gwendolyn Wu
-
Orum, a biotech marrying ADCs with protein degraders, captures $100M in funding
Dec. 18, 2025 -
Addition emerges with $100M to make gene therapies for chronic and rare diseases
Dec. 17, 2025 -
‘Zombie’ biotech buyer Xoma to acquire Generation Bio
Dec. 16, 2025 -
Biotech venture firm Apple Tree goes bankrupt amid dispute with billionaire backer
Dec. 11, 2025 -
Prolynx banks $70M for longer-lasting obesity drugs
Dec. 11, 2025 -
A Roivant spinout bets on AI-designed drugs for immune conditions
Dec. 10, 2025 -
Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay
Dec. 8, 2025 -
With $130M, Protego pushes forward a new type of amyloidosis drug
Dec. 1, 2025 -
Aspen raises $115M for a Parkinson’s stem cell treatment
Nov. 20, 2025 -
Zymeworks to change course, pursue ‘royalty-driven’ biotech model
Nov. 18, 2025 -
A ‘DNA damage repair’ drugmaker raises $115M for cancer treatments
Nov. 17, 2025 -
Sofinnova Partners raises another $750M to back biotech, medtech startups
Nov. 16, 2025 -
Medicxi closes sixth fund to back ‘asset-centric’ startups
Nov. 14, 2025 -
Lilly picks up an eye gene therapy in deal with MeiraGTx
Nov. 10, 2025 -
AstraZeneca exercises option to buy an obesity startup
Nov. 6, 2025 -
Evommune nabs $150M in IPO amid federal shutdown
Nov. 5, 2025 -
Corporate venture firms stepped in for drug startups during biotech funding pullback
Oct. 31, 2025 -
Zag Bio emerges with plans to treat immune disease by targeting the thymus
Oct. 28, 2025 -
Electra nabs $183M for its rare disease drug ambitions
Oct. 22, 2025 -
Flagship bets again on AI with Expedition
Oct. 22, 2025 -
Cancer drug startup Tubulis raises $361 million for ADCs
Oct. 15, 2025 -
A young biotech nets $70M for a new type of allergy drug
Oct. 13, 2025 -
Evommune files for IPO to advance immune drug work
Oct. 10, 2025 -
MapLight uses workaround to tee up IPO during government shutdown
Oct. 7, 2025 -
Chiesi buys into Arbor gene editing drug for rare kidney disease
Oct. 6, 2025